Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.65 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.65 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.57 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31065139 | 1.00 | IKZF2 (0.65) | IKZF2IKZF1CRBNCSNK1A1 | |
| Hydrochloric Acid SCHEMBL29663710 | 0.99 | IKZF2 (0.64) | IKZF2IKZF1CRBNCSNK1A1 | |
| Hydrochloric Acid SCHEMBL25415969 | 0.99 | IKZF2 (0.64) | IKZF2IKZF1CRBNCSNK1A1 | |
| SCHEMBL25010615 | 0.93 | IKZF2 (0.69) | IKZF2IKZF1CRBNCSNK1A1 | |
| Toluene SCHEMBL29119909 | 0.92 | IKZF2 (0.59) | IKZF2IKZF1CRBNCSNK1A1 | |
| SCHEMBL23105167 | 0.88 | IKZF2 (0.69) | IKZF2IKZF1CRBN | |
| SCHEMBL23093387 | 0.88 | IKZF2 (0.59) | IKZF2IKZF1CRBN | |
| SCHEMBL23509532 | 0.87 | IKZF2 (0.68) | IKZF2IKZF1CRBN | |
| SCHEMBL30798528 | 0.85 | IKZF2 (0.57) | IKZF2IKZF1CRBN | |
| SCHEMBL22557008 | 0.85 | CRBN (0.69) | IKZF2IKZF1CRBNCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12522612-B2 | PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications | BIOTHERYX INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4662208-A1 | COMPOUNDS AND COMPOSITIONS FOR SELECTIVE DEGRADATION OF ENGINEERED PROTEINS | Celgene Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025245178-A1 | PAK4, CSTF2, OR CSTF2T PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | INNOVO THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250186434-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20240327381-A1 | Compounds and Compositions for Selective Degradation of Engineered Proteins | CELGENE CORPORATION (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024167999-A1 | COMPOUNDS AND COMPOSITIONS FOR SELECTIVE DEGRADATION OF ENGINEERED PROTEINS | CELGENE CORPORATION (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024151557-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240124418-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023023531-A1 | ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023531-A1 | ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4073074-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022132603-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| WO-2022061348-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2021155050-A1 | KINASE MODULATORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021119571-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021051034-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | IKZF2 2777/4885IKZF1 2582/4885CRBN 245/4885 |
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, RXFP3, NPY2R | IKZF2 4560/4885IKZF1 3715/4885CRBN 3673/4885 |
| US-20240327381-A1 | Compounds and Compositions for Selective Degradation of Engineered Proteins | TP53, APC, MDM2 | IKZF2 1146/4885IKZF1 646/4885CRBN 19/4885 |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KRAS, RSU1, RAB1A | IKZF2 2454/4885IKZF1 2956/4885CRBN 407/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | IKZF2 2621/4885IKZF1 1510/4885CRBN 474/4885 |
| US-20240124418-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | PDE4A, PDE4B, PDE12 | IKZF2 4771/4885IKZF1 4075/4885CRBN 2742/4885 |
| US-20250186434-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, CUL1, SOS2 | IKZF2 2235/4885IKZF1 1023/4885CRBN 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.